AG
BLCM

Algert Global’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Algert Global’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,681
Closed -$47K – 553
2019
Q4 		$47K Sell
3,681
-5,376
-59% -$49.6K 0.01% 364
2019
Q3 		$95K Buy
9,057
+591
+7% +$7.72K 0.04% 330
2019
Q2 		$144K Buy
+8,466
New +$229K 0.05% 304

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Algert Global's BLCM Position: Q1 2020 in Review

Algert Global sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2020, closing a stake of 3,681 shares — an estimated $47K sold.

Algert Global first reported a position in BLCM in Q2 2019 and held it in 3 quarters. The position peaked at $144K in Q2 2019. 29 funds tracked by Wall St. Rank hold BLCM as of Q1 2020.

  • Algert Global reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Algert Global sold 3,681 Bellicum Pharmaceuticals, Inc. shares in Q1 2020, an estimated $47K.
  • Algert Global first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2019 and held it in 3 quarters.
  • Algert Global's Bellicum Pharmaceuticals, Inc. position peaked at $144K in Q2 2019.
  • 29 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2020.

Based on Algert Global's 13F filing for Q1 2020, filed 13 May 2020.